^
1m
Evaluate the Efficacy, Safety and Tolerability of HLX26 and Serplulimab in Patients with MCRC (clinicaltrials.gov)
P2, N=2, Terminated, Shanghai Henlius Biotech | N=49 --> 2 | Trial completion date: Apr 2026 --> Dec 2023 | Suspended --> Terminated | Trial primary completion date: Aug 2024 --> Dec 2023; Due to poor clinical trial accrual, the study was terminated.
Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Combination therapy
|
KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene)
|
BRAF mutation • KRAS wild-type • RAS wild-type
|
Hetronifly (serplulimab) • HLX26
9ms
Trial completion • Enrollment change • Metastases
|
HLX26
9ms
Enrollment change
|
PD-L1 (Programmed death ligand 1) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • LAG3 (Lymphocyte Activating 3)
|
PD-L1 expression • ROS1 rearrangement • LAG3 expression
|
carboplatin • albumin-bound paclitaxel • Hetronifly (serplulimab) • HLX26
9ms
Trial completion
|
ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
Hetronifly (serplulimab) • HLX26
1year
Safety, preliminary efficacy, and pharmacokinetics of HLX26 plus serplulimab in advanced solid tumours: An open-label, dose-escalation phase I study (ESMO Asia 2023)
Conclusions No new safety signals were observed for the different doses of HLX26 in combination with serplulimab. HLX26 plus serplulimab was safe and well tolerated in patients with advanced solid tumours who had failed or could not receive standard therapies.
Clinical • P1 data • PK/PD data • Metastases
|
Hetronifly (serplulimab) • HLX26
1year
Enrollment open • Metastases
|
PD-L1 (Programmed death ligand 1) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • LAG3 (Lymphocyte Activating 3)
|
PD-L1 expression • ROS1 rearrangement • LAG3 expression
|
carboplatin • albumin-bound paclitaxel • pemetrexed • Hetronifly (serplulimab) • HLX26
1year
Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of HLX26 and HLX10 in Patients With Advanced/Metastatic Solid Tumor (clinicaltrials.gov)
P1, N=6, Active, not recruiting, Shanghai Henlius Biotech | Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2023 --> Aug 2023
Enrollment closed • Trial primary completion date • Combination therapy • Metastases
|
ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
Hetronifly (serplulimab) • HLX26
over1year
Trial suspension • Combination therapy
|
KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene)
|
BRAF mutation • KRAS wild-type • RAS wild-type
|
Hetronifly (serplulimab) • HLX26
over1year
Evaluate the Efficacy, Safety and Tolerability of HLX26 and Serplulimab in Patients With mCRC (clinicaltrials.gov)
P2, N=49, Recruiting, Shanghai Henlius Biotech | Trial completion date: Nov 2023 --> Apr 2026 | Trial primary completion date: Aug 2023 --> Aug 2024
Trial completion date • Trial primary completion date • Combination therapy
|
KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene)
|
BRAF mutation • KRAS wild-type • RAS wild-type
|
Hetronifly (serplulimab) • HLX26
over1year
Evaluate the Efficacy, Safety and Tolerability of HLX26 and Serplulimab in Patients With mCRC (clinicaltrials.gov)
P2, N=49, Recruiting, Shanghai Henlius Biotech | Not yet recruiting --> Recruiting | Initiation date: Nov 2022 --> May 2023
Enrollment open • Trial initiation date
|
KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene)
|
BRAF mutation • KRAS wild-type • RAS wild-type
|
Hetronifly (serplulimab) • HLX26
over1year
New P2 trial • Metastases
|
PD-L1 (Programmed death ligand 1) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • LAG3 (Lymphocyte Activating 3)
|
PD-L1 expression • ROS1 rearrangement • LAG3 expression
|
carboplatin • albumin-bound paclitaxel • pemetrexed • Hetronifly (serplulimab) • HLX26
2years
New P2 trial • Combination therapy • Metastases
|
KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene)
|
BRAF mutation • KRAS wild-type • RAS wild-type
|
Hetronifly (serplulimab) • HLX26
2years
Enrollment open • Combination therapy • Metastases
|
ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
Hetronifly (serplulimab) • HLX26
over2years
Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of HLX26 and HLX10 in Patients With Advanced/Metastatic Solid Tumor (clinicaltrials.gov)
P1, N=6, Not yet recruiting, Shanghai Henlius Biotech | Trial completion date: Jan 2023 --> Dec 2023 | Trial primary completion date: Jan 2023 --> Dec 2023
Trial completion date • Trial primary completion date • Combination therapy
|
ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
Hetronifly (serplulimab) • HLX26
over2years
New P1 trial • Combination therapy
|
ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
Hetronifly (serplulimab) • HLX26